Edwards George A, Wood Caleb A, Nguyen Quynh, Kim Peter J, Gomez-Gutierrez Ruben, Park Kyung-Won, Zurhellen Cody, Al-Ramahi Ismael, Jankowsky Joanna L
bioRxiv. 2023 Mar 25:2023.03.23.533978. doi: 10.1101/2023.03.23.533978.
TMEM106B is a risk modifier for a growing list of age-associated dementias including Alzheimer’s and frontotemporal dementia, yet its function remains elusive. Two key questions that emerge from past work are whether the conservative T185S coding variant found in the minor haplotype contributes to protection, and whether the presence of TMEM106B is helpful or harmful in the context of disease. Here we address both issues while extending the testbed for study of TMEM106B from models of TDP to tauopathy. We show that TMEM106B deletion accelerates cognitive decline, hindlimb paralysis, neuropathology, and neurodegeneration. TMEM106B deletion also increases transcriptional overlap with human AD, making it a better model of disease than tau alone. In contrast, the coding variant protects against tau-associated cognitive decline, neurodegeneration, and paralysis without affecting tau pathology. Our findings show that the coding variant contributes to neuroprotection and suggest that TMEM106B is a critical safeguard against tau aggregation.
跨膜蛋白106B(TMEM106B)是越来越多与年龄相关的痴呆症(包括阿尔茨海默病和额颞叶痴呆)的风险调节因子,但其功能仍不清楚。过去的研究提出了两个关键问题:在次要单倍型中发现的保守编码变体T185S是否具有保护作用,以及在疾病背景下TMEM106B的存在是有益还是有害。在这里,我们在将TMEM106B的研究试验台从TDP模型扩展到tau蛋白病模型的同时,解决了这两个问题。我们发现,删除TMEM106B会加速认知衰退、后肢麻痹、神经病理学和神经退行性变。删除TMEM106B还会增加与人类阿尔茨海默病的转录重叠,使其比单独的tau蛋白病模型更能模拟疾病。相比之下,编码变体可防止tau蛋白相关的认知衰退、神经退行性变和麻痹,而不影响tau蛋白病理。我们的研究结果表明,该编码变体具有神经保护作用,并提示TMEM106B是防止tau蛋白聚集的关键保护因子。